Navigation Links
Savient Announces Appointment of David Gionco as Chief Financial Officer
Date:2/12/2009

EAST BRUNSWICK, N.J., Feb. 12 /PRNewswire-FirstCall/ -- Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) today announced the appointment of David G. Gionco to the position of Vice President, Chief Financial Officer & Treasurer. Mr. Gionco replaces Brian Hayden, who has been terminated as Savient's Chief Financial Officer, effective immediately.

"We are pleased to announce David's appointment. As our current Vice President of Corporate Finance and Controller, David will be able to seamlessly step in as Chief Financial Officer. Since joining Savient in 2006, David has distinguished himself as a true leader in the financial and operational areas. David's experience and dedication makes him well-suited to lead our finance and accounting departments. I look forward to working with David in the months ahead as we continue to move through the FDA regulatory process and towards what we hope will be a successful approval of KRYSTEXXA(TM) (pegloticase)," said Paul Hamelin, President, Savient Pharmaceuticals.

Mr. Gionco has spent more than 18 years in the pharmaceutical industry, including the past three years with Savient where he most recently served as Vice President of Corporate Finance and Controller. Through his career, Mr. Gionco has held various audit, corporate accounting, financial planning, finance and controller roles of increasing responsibility at companies including Medco, Merck & Co., Progenics Pharmaceuticals and Odyssey Pharmaceuticals, where he served as Acting Chief Financial Officer/Director of Finance and Controller before joining Savient. In addition, Mr. Gionco has 7 years of financial auditing experience with a major public accounting firm. Mr. Gionco holds a B.S. in Accounting from Fairleigh Dickinson University and an MBA from Rutgers University.

A
'/>"/>

SOURCE Savient Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Savient Pharmaceuticals to Present at the Lazard Capital Markets 5th Annual Healthcare Conference on November 18th
2. Savient Pharmaceuticals Reports Third Quarter 2008 Financial Results
3. Savient Submits Biologics License Application (BLA) for pegloticase
4. Savients Pegloticase Data in Treatment-Failure Gout Patients Presented at 72nd Annual Meeting of the American College of Rheumatology Conference
5. Savient Pharmaceuticals to Hold Third Quarter 2008 Financial Results Conference Call on Thursday, November 6, 2008
6. Vermillion Announces Notice of Issuance of U.S. Patent Covering Hepcidin as a Biomarker for Ovarian Cancer
7. SENOMYX ANNOUNCES FOURTH QUARTER AND YEAR-END 2008 FINANCIAL RESULTS
8. Genesis Pharmaceuticals Announces Conference Call to Discuss Results for its Second Quarter of FY 2009
9. Cord Blood Announces $1 Million Reduction in Long Term Debt
10. BioMed Realty Trust Announces New Financing for Joint Venture With Prudential Real Estate Investors
11. XTL Biopharmaceuticals Announces Appointment of David Grossman and Boaz Shweiger to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... July 28, 2014 Research and Markets ... Synthetic Biology Market 2014-2018" report to their offering. ... The term synthetic biology covers the designing and engineering ... well as the redesigning of natural biological systems that ... be a form of extreme genetic engineering because it ...
(Date:7/28/2014)... 28, 2014 According ... Market by Products (Consumables, Instruments, Services), Methods (Phenotypic, Genotypic), Applications (Pharmaceutical, ... (Detection, Characterization) - Global Forecasts to 2019" ... is estimated at $896.5 Million in 2014 ... by 2019, growing at a CAGR of ...
(Date:7/28/2014)... Boston, MA (PRWEB) July 28, 2014 ... with two researchers to further develop potential treatments for ... brain tumor, in combination with their patented vaccine platform, ... and Duke University, are based on the work of ... of Neurosurgery at The Preston Robert Tisch Brain Tumor ...
(Date:7/28/2014)... St Louis, MO (PRWEB) July 28, 2014 ... tools, software, and services that bring the power of ... for the inaugural Appistry Pipeline Challenge . ... Callum Bell, president of the National Center for Genome ... Children’s Mercy Hospitals and Clinics of Kansas City. Rounding ...
Breaking Biology Technology:Global Synthetic Biology Market 2014-2018 2Microbial Identification Market worth $1,194.1 Million by 2019 2Microbial Identification Market worth $1,194.1 Million by 2019 3String of Collaborations Launch Immunomic Therapeutics’ Brain Tumor Program Pipeline 2String of Collaborations Launch Immunomic Therapeutics’ Brain Tumor Program Pipeline 3String of Collaborations Launch Immunomic Therapeutics’ Brain Tumor Program Pipeline 4Appistry Names Industry Experts from the National Center for Genome Resources and Mercy Children's, Kansas City, to Judge Pipeline Challenge Competition 2
... 7, 2011 Reportlinker.com announces that a new ... Industrial Biotechnology China News 1103 ... The Chinese central government was reported to continue ... the Twelfth Five-Year (2011-2015) Plan. This act is ...
... and industrial research scientists and engineers, as well ... encounter a steep learning curve when developing common ... book just published by Springer promises to be ... The new MEMS Materials and Processes Handbook is ...
... The U.S. Food and Drug Administration today approved ... tool to treat brain aneurysms without performing open surgery. ... An aneurysm is a weak, enlarged area in an ... blood pressure can cause it to rupture, which can ...
Cached Biology Technology:Reportlinker Adds Industrial Biotechnology China News 1103 2Reportlinker Adds Industrial Biotechnology China News 1103 3MEMS Materials and Processes Handbook -- a comprehensive, practical resource 2FDA Approves New Device to Treat Brain Aneurysms 2FDA Approves New Device to Treat Brain Aneurysms 3
(Date:7/28/2014)... advance the genetic engineering of "fuel" crops for ... by researchers with the U.S. Department of Energy ... led by Lawrence Berkeley National Laboratory (Berkeley Lab). ... enables scientists to identify and characterize the function ... biosynthesis of plant cell walls. , "Our unique ...
(Date:7/28/2014)... virus killers to prevent and treat HIV infection has ... response these molecules can arouse as they get rid ... at the Weizmann Institute and the National Institutes of ... these molecules interferons around the time of ... the disease. Their research appeared in Nature . ...
(Date:7/28/2014)... Institute for Biologically Inspired Engineering at Harvard University ... be commercialized by a newly formed private company ... personalized medicine products. The announcement follows ... Technology Development (OTD) and the start-up Emulate Inc., ... human Organs-on-Chips platform. , "This is a ...
Breaking Biology News(10 mins):How sweet it is 2How sweet it is 3Interfering with interferon 2Wyss Institute's technology translation engine launches 'Organs-on-Chips' company 2Wyss Institute's technology translation engine launches 'Organs-on-Chips' company 3
... light, Stacie Grassano pulls out a tube. "This is a great ... Inside, a tree branch is speckled with white fluff. "It's growing ... brings the branch close to his eye. "Yes," he says, with ... For some, a fungus success story means nothing is growing at ...
... reveal in the 29 March 2007 issue of the ... important structures that control how genes are packaged and ... time, we are seeing in very high resolution on ... an organism's genes," said B. Franklin Pugh, professor of ...
... into a box glowing with fluorescent light, Stacie Grassano pulls out ... clear plastic up to her face. Inside, a tree branch is ... it to Scott Costa. , Costa brings the branch close to ... a fungus success story." , For some, a fungus success ...
Cached Biology News:Immunization rates hit record high in poor countries 2Immunization rates hit record high in poor countries 3Scientists reveal structure of gateways to gene control 2Scientists reveal structure of gateways to gene control 3Scientists reveal structure of gateways to gene control 4Fungal factories may save hemlock forests 2Fungal factories may save hemlock forests 3
Mouse monoclonal antibody raised against a partial recombinant STAU2. NCBI Entrez Gene ID = STAU2...
...
Mouse polyclonal antibody to NR2F2 - nuclear receptor subfamily 2, group F, member 2...
... Hybridization Wash Pack provides optimized blocking ... Preparation Quality Clarifier: Ready-to-use wash solutions ... SigmaScreen(tm) APS Coated Slides for Microarrays ... Hybridization Blocking Buffer: 1L • Microarray ...
Biology Products: